Enliven Therapeutics, Inc.
NASDAQ:ELVNBiotechnology
-$0.12 today
- Market cap
- $3.30B
- Beta
- 0.40
- P/E (TTM)
- -28.4
- EPS (TTM)
- -$1.57
Volume 0.75M
Average 1.35M
ELVN Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Enliven Therapeutics, Inc.NASDAQ: ELVN
Total Equity · Q3 FY2026 · quarter ended Sep 2026
Total equity rises 84.2% from a year ago
Total equity stood at $876.95M at the end of Q3 FY2026, up 84.2% from a year earlier and down 2.0% from the prior quarter.
Context
- Total equity amounted to 97.7% of total assets at the end of Q3 FY2026, up 0.7 pp from a year earlier.
- Total equity increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +84.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 459.6M USD
- Year-over-year change
- +48.3%
- 4-year CAGR
- +44.0%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 459.6M | +48.3% |
| FY2024 | 2024-12-31 | 309.85M | +26.0% |
| FY2023 | 2023-12-31 | 245.91M | +420.1% |
| FY2022 | 2022-12-31 | (76.83M) | -171.9% |
| FY2021 | 2021-12-31 | 106.86M | — |
Total Equity vs competitors
How ELVN compares with its peers on the latest reported figures
- ELVN's Sep 2026 total equity of $876.95M is the 5th highest of the 11 companies compared; the peer median is $401.57M.
- Its year-over-year change of +84.2% is the 2nd highest of 11, against a peer median of +26.7%.
- Total equity amounts to 97.7% of total assets for ELVN, versus a peer median of 85.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $6.34B | +52.1% | +5.7% | 80.6% | |
| Jun 2026 | $2.61B | +39.7% | +33.5% | 60.3% | |
| Jul 2026 | $1.84B | -9.3% | -4.6% | 73.9% | |
| Jun 2026 | $890.01M | +33.7% | -15.8% | 92.0% | |
| Sep 2026 | $876.95M | +84.2% | — | 97.7% | |
| Mar 2026 | $415.56M | +89.1% | +20.0% | 95.1% | |
| Mar 2026 | $387.58M | +19.8% | +0.2% | 94.1% | |
| Mar 2026 | $366.17M | -33.6% | -8.6% | 90.9% | |
| Mar 2026 | $323.98M | +60.0% | +20.8% | 92.8% | |
| Jun 2026 | $253.86M | -31.9% | -22.4% | 34.1% | |
| Mar 2026 | $41.62M | -80.6% | -48.3% | 8.8% | |
| Peer median (excluding ELVN) | $401.57M | +26.7% | -2.2% | 85.7% | |
Competitors are the stored peer set for ELVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 110.02M | 75.54M | 100.14M | 124.12M | 98.9M |
| Short-term Investments | 0 | 0 | 153.01M | 189.32M | 363.73M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 2.22M | 10.05M | 4.69M | 12.26M |
| Total Current Assets | 110.67M | 77.75M | 266.15M | 318.13M | 474.88M |
| Property, Plant & Equipment (Net) | 954K | 1.52M | 1.06M | 458K | 417K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 54K | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.71M | 3.98M | 4.65M | 7.18M | 873K |
| Total Non-current Assets | 2.66M | 5.55M | 5.72M | 7.63M | 1.29M |
| Total Assets | 113.33M | 83.3M | 271.87M | 325.76M | 476.17M |
| Account Payables | 2.52M | 3.44M | 532K | 1.34M | 2.16M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 5.51M | 0 | 0 | 0 |
| Other Current Liabilities | 233K | 320K | 10.36M | 204K | 4.65M |
| Total Current Liabilities | 5.75M | 9.72M | 25.89M | 15.92M | 16.57M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 108K |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 714K | 150.41M | 67K | 0 | 0 |
| Total Non-current Liabilities | 714K | 150.41M | 67K | 0 | 108K |
| Total Liabilities | 6.47M | 160.12M | 25.96M | 15.92M | 16.68M |
| Common Stock | 1K | 1K | 41K | 49K | 59K |
| Retained Earnings | (45.2M) | (82.86M) | (154.45M) | (243.47M) | (347.17M) |
| Accumulated OCI | 0 | (149.75K) | 141K | 55K | 334K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 106.86M | (76.83M) | 245.91M | 309.85M | 459.6M |
| Total Debt | 159K | 323K | 335K | 0 | 399K |
| Net Debt | (109.87M) | (75.21M) | (99.81M) | (124.12M) | (98.5M) |
Enliven Therapeutics, Inc.
NASDAQ:ELVN
Intrinsic Alpha fair value
Locked
Current Price
$44.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.